Regeneron Pharmaceuticals (REGN) News Today → 'If I Die, I’d Trust 50% of My Daughters’ Inheritance in ONE Stock.' (From Stansberry Research) (Ad) Free REGN Stock Alerts $1,001.83 +0.10 (+0.01%) (As of 12:39 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 11 at 9:41 AM | marketbeat.comBellevue Group AG Sells 4,230 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Bellevue Group AG lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 28.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,709 shares of the biopharmaceuticaJune 11 at 7:00 AM | globenewswire.comKevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)June 11 at 4:42 AM | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Leonard S. Schleifer Sells 787 SharesJune 10 at 11:30 PM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Bridgewater Associates LPBridgewater Associates LP raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 81.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 110,132 shares of the biopharmaceutJune 10 at 4:21 PM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Sells $798,820.74 in StockRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) CEO Leonard S. Schleifer sold 787 shares of the business's stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $1,015.02, for a total transaction of $798,820.74. Following the completion of the sale, the chief executive officer now owns 64,198 shares of the company's stock, valued at approximately $65,162,253.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.June 10 at 12:56 AM | marketbeat.comCambridge Investment Research Advisors Inc. Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Cambridge Investment Research Advisors Inc. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 35.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owneJune 9 at 12:17 AM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Morgens Waterfall Vintiadis & Co. Inc.Morgens Waterfall Vintiadis & Co. Inc. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 173.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,100 shares of the biopharmaceutJune 8 at 9:04 AM | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Bonnie L. Bassler Sells 827 Shares of StockJune 8 at 8:30 AM | insidertrades.comBonnie L. Bassler Sells 827 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockJune 7, 2024 | fool.comStock Split Watch: 3 Growth Stocks That Could Be NextJune 7, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Public Employees Retirement Association of ColoradoPublic Employees Retirement Association of Colorado raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,074 shares of tJune 6, 2024 | marketbeat.comTop Biotech Stocks: Exploring Innovation Opportunities (REGN)One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccinesJune 6, 2024 | marketbeat.comCapital World Investors Buys 23,146 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Capital World Investors grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,130,485 shares of the biopharmaceutJune 6, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $1,200.00June 5, 2024 | marketbeat.comCibc World Markets Corp Purchases 21,325 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Cibc World Markets Corp lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 117.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,496 shares of the biopharmaceJune 5, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNJune 5, 2024 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript)June 4, 2024 | marketbeat.comRhenman & Partners Asset Management AB Has $34.25 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Rhenman & Partners Asset Management AB reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,000 shares ofJune 3, 2024 | insidermonkey.comIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?June 3, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Rafferty Asset Management LLCRafferty Asset Management LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,176 shares of the biopharmaceJune 3, 2024 | marketbeat.comRegeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month High at $1,000.72Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 1-Year High at $1,000.72June 3, 2024 | marketbeat.com801 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Robinson Smith Wealth Advisors LLCRobinson Smith Wealth Advisors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 801 shares of the biopharmaceutical company's stock, valued at apprJune 2, 2024 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of "Moderate Buy" by BrokeragesJune 1, 2024 | marketbeat.comBOCHK Asset Management Ltd Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)BOCHK Asset Management Ltd bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,800 shares of the biopharmaceuMay 31, 2024 | globenewswire.comPress Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDMay 31, 2024 | globenewswire.comDupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDMay 31, 2024 | globenewswire.comPress Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationMay 31, 2024 | globenewswire.comUpdate on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNMay 30, 2024 | marketbeat.comTD Asset Management Inc Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)TD Asset Management Inc lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 43.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,513 shares of the biophaMay 30, 2024 | insidertrades.comMichael S. Brown Sells 1,172 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 29, 2024 | marketbeat.comTFO Wealth Partners LLC Has $1.03 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)TFO Wealth Partners LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 58,400.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,170 shares of the biopMay 29, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Sells $1,142,535.92 in StockRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Michael S. Brown sold 1,172 shares of the firm's stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the transaction, the director now owns 1,382 shares of the company's stock, valued at approximately $1,347,256.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.May 29, 2024 | prnewswire.comBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsMay 25, 2024 | marketbeat.comIntech Investment Management LLC Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Intech Investment Management LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 119.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,593 shares of the biophMay 25, 2024 | fool.com2 Biotech Stocks to Buy in MayMay 23, 2024 | globenewswire.comPromising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCOMay 23, 2024 | businesswire.comMary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering FairMay 23, 2024 | marketbeat.comOntario Teachers Pension Plan Board Sells 995 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Ontario Teachers Pension Plan Board cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,971 shares ofMay 23, 2024 | marketbeat.comRegeneron Pharmaceuticals Q1 Earnings TranscriptMay 23, 2024 | fool.com3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 YearsMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNMay 22, 2024 | finance.yahoo.comIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?May 21, 2024 | marketbeat.comDakota Wealth Management Purchases New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Dakota Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,372 shares of the biopharmaceutical companMay 20, 2024 | marketbeat.comAssetmark Inc. Acquires 1,552 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Assetmark Inc. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,171 shares of the biopharmaceutical company's stockMay 20, 2024 | globenewswire.comDupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of MedicineMay 20, 2024 | globenewswire.comPress Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJMMay 20, 2024 | investorplace.com7 Biotech Stocks That Could Breathe New Life Into Your PortfolioMay 19, 2024 | marketbeat.com1,061,803 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Norges BankNorges Bank bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,061,803 shares of the biopharmaceutical company's stock,May 19, 2024 | marketbeat.comING Groep NV Has $24.87 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)ING Groep NV reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 20.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,311 shares of the biopharmaceutical company's stock af Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Don’t make this retirement mistake (Ad)If you have over $100,000 in your 401K or IRA… Then listen closely… Your money is rotting away, and you might not even realize it. Reserve your seat here. REGN Media Mentions By Week REGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGN News Sentiment▼0.640.74▲Average Medical News Sentiment REGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGN Articles This Week▼2015▲REGN Articles Average Week Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Amgen News Vertex Pharmaceuticals News Gilead Sciences News Biogen News Alnylam Pharmaceuticals News Royalty Pharma News BioMarin Pharmaceutical News BeiGene News Neurocrine Biosciences News Incyte News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REGN) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does ...Porter & Company | SponsoredThe Greatest LEGAL Transfer of Wealth in History is UnderwayWhat's the #1 Stock to Build Generational Wealth RIGHT NOW? One Wall Street millionaire will give you a sur...Stansberry Research | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored